Bruker Co. (NASDAQ:BRKR) CEO Purchases $5,014,000.00 in Stock

Bruker Co. (NASDAQ:BRKR) CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were purchased at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the purchase, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Bruker Price Performance

Shares of NASDAQ BRKR traded down $1.16 during trading on Tuesday, hitting $48.25. 1,402,280 shares of the company were exchanged, compared to its average volume of 1,085,836. The company has a market cap of $7.31 billion, a price-to-earnings ratio of 23.75, a PEG ratio of 2.46 and a beta of 1.20. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The firm’s fifty day moving average price is $62.32 and its 200 day moving average price is $65.07. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company’s quarterly revenue was up 16.4% compared to the same quarter last year. During the same period last year, the firm earned $0.74 EPS. On average, sell-side analysts expect that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.41%. The ex-dividend date is Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC raised its stake in shares of Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares during the last quarter. State Street Corp raised its stake in Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after purchasing an additional 318,808 shares during the last quarter. RTW Investments LP raised its stake in Bruker by 1.1% in the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after purchasing an additional 37,024 shares during the last quarter. Geode Capital Management LLC raised its stake in Bruker by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after purchasing an additional 193,580 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in Bruker by 127.8% in the 2nd quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after purchasing an additional 779,549 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on BRKR shares. Wells Fargo & Company dropped their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Barclays dropped their price target on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Citigroup dropped their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. TD Cowen dropped their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Finally, Wolfe Research lowered shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Bruker has a consensus rating of “Moderate Buy” and an average price target of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.